These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7279807)

  • 1. Response criteria for the prostate of the USA National Prostatic Cancer Project.
    Murphy GP; Slack NH
    Prostate; 1980; 1(3):375-82. PubMed ID: 7279807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decade of experience with chemotherapy for prostate cancer.
    Slack NH; Murphy GP
    Urology; 1983 Jul; 22(1):1-7. PubMed ID: 6346631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for prostate carcinoma.
    Eisenberger MA
    NCI Monogr; 1988; (7):151-63. PubMed ID: 3050534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of chemotherapy programs of the NPCP.
    Slack NH; Murphy GP
    Prostate; 1980; 1(3):367-73. PubMed ID: 7279806
    [No Abstract]   [Full Text] [Related]  

  • 5. The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer.
    Slack NH; Mittelman A; Brady MF; Murphy GP
    Cancer; 1980 Dec; 46(11):2393-402. PubMed ID: 7002280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer.
    Herr HW
    J Urol; 1982 Mar; 127(3):462-5. PubMed ID: 7062419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperative clinical of single and combined agent protocols: adjuvant protocols. National Prostatic Cancer Project Cooperative Clinical Trials.
    Gibbons RP
    Urology; 1981 Apr; 17(4 Suppl):48-52. PubMed ID: 7010762
    [No Abstract]   [Full Text] [Related]  

  • 8. Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma.
    Labrie F; Dupont A; Giguere M; Cusan L; Bergeron N; Emond J; Monfette G; Lacourciere Y; Boucher H; Lachance R
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1869-78. PubMed ID: 3220084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
    Eisenberger MA; Simon R; O'Dwyer PJ; Wittes RE; Friedman MA
    J Clin Oncol; 1985 Jun; 3(6):827-41. PubMed ID: 2409240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy to definitive treatment of prostate cancer.
    Loening S; Narayana A
    Prostate; 1980; 1(3):321-35. PubMed ID: 7024955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of trials of the USA National Prostatic Cancer Project.
    Elder JS; Gibbons RP
    Prog Clin Biol Res; 1985; 185A():221-42. PubMed ID: 3898131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
    Murphy GP; Priore RL; Scardino PT
    Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
    Peeling WB
    Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone.
    Murphy GP; Beckley S; Brady MF; Chu TM; deKernion JB; Dhabuwala C; Gaeta JF; Gibbons RP; Loening SA; McKiel CF; McLeod DG; Pontes JE; Prout GR; Scardino PT; Schlegel JU; Schmidt JD; Scott WW; Slack NH; Soloway MS
    Cancer; 1983 Apr; 51(7):1264-72. PubMed ID: 6337697
    [No Abstract]   [Full Text] [Related]  

  • 16. A reexamination of the stable category for evaluating response in patients with advanced prostate cancer.
    Slack NH; Brady MF; Murphy GP
    Cancer; 1984 Aug; 54(3):564-74. PubMed ID: 6375857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
    Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of hormonally unresponsive prostatic carcinoma.
    deKernion JB; Lindner A
    Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytostatic therapy of prostatic carcinoma. Current status and personal results].
    Nagel R; Leistenschneider W
    Urologe A; 1983 Sep; 22 Suppl():304-9. PubMed ID: 6356555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Criteria for evaluating patient responses to treatment modalities for prostatic cancer.
    Slack NH; Murphy GP
    Urol Clin North Am; 1984 May; 11(2):337-42. PubMed ID: 6375069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.